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BACKGROUND & AIMS: We studied the reliability of
the previously described Ulcerative Colitis Endoscopic
Index of Severity (UCEIS) and validated it with an inde-
pendent cohort of investigators. METHODS: We created
a new library of 57 videos of ﬂexible sigmoidoscopy and
stratiﬁed them based on disease severity. Twenty-ﬁve
investigators were each randomly assigned to assess
28 videos (which included 4 duplicates to assess intra-
observer reliability). Investigators were blinded to clinical
details except for 2 of 4 duplicated videos (to assess the
impact of knowledge of symptoms on assessment). Three
descriptors (“vascular pattern”, “bleeding”, and “erosions
and ulcers”) comprising the UCEIS were scored with a
visual analogue scale (VAS) to assess overall severity.
Intrainvestigator and interinvestigator agreement was
characterized by k statistical analysis; reliability ratios were
used to compare VAS and UCEIS scores. RESULTS: There
was a high level of correlation between UCEIS scores and
overall assessment of severity (correlation coefﬁcient,
0.93). Internal consistency (Cronbach a analysis) was 0.86.
Intrainvestigator and interinvestigator reliability ratios for
UCEIS scores were 0.96 and 0.88, respectively. Intra-
investigator agreement in determination of the UCEIS
score was good (k ¼ 0.72), with individual descriptors
ranging from a k of 0.47 (for bleeding) to 0.87 (for
vascular pattern). Interinvestigator agreement in determi-
nation of UCEIS scores was moderate (k ¼ 0.50), with
descriptors ranging from a k of 0.48 (for bleeding) to 0.54
(for vascular pattern). Intrainvestigator variability in
determining UCEIS scores did not change appreciably
when a video was presented with clinical details.
CONCLUSIONS: The UCEIS and its components
show satisfactory intrainvestigator and interinvesti-
gator reliability. Among investigators, the UCEIS
accounted for a median of 86% of the variability inevaluation of overall severity on the VAS when
assessing the endoscopic severity of UC and was
unaffected by knowledge of clinical details.
Keywords: Endoscopic Score; Endoscopic Severity; Inﬂam-
matory Bowel Disease; Disease Activity.
ndoscopy is extremely valuable for evaluating theEefﬁcacy of new treatments for patients with ulcerative
colitis (UC).1,2 However, valid endoscopic scoring systems
are needed to standardize end points and facilitate
meaningful comparisons.3 Interobserver variation in
endoscopic assessment of disease severity may alter clinical
trial outcomes and have a substantial effect on therapeutic
or regulatory decisions.4 Several activity indices for UC
incorporate endoscopic data, with the Mayo Clinic Index or
the Ulcerative Colitis Disease Activity Index commonly used
in trials conducted to seek regulatory approval,1 but these
instruments have not undergone appropriate validation or
rigorous reliability assessment.1,5 To address the need for a
highly dependable instrument for assessing the endoscopic
severity of UC, we evaluated variations in the overall endo-
scopic assessment of disease severity, as well as intra-
individual and interindividual variations of descriptive
terms (“descriptors”), to create the Ulcerative Colitis Endo-
scopic Index of Severity (UCEIS).6 The UCEIS was developed
in 2 phases: (1) the level of disagreement among in-
vestigators and 10 descriptors, each with 3 to 5 levels of
severity, was determined and (2) interobserver and intra-
observer variability for each descriptor was investigated.
A model was then constructed that best represented overall
endoscopic severity evaluated on a visual analogue scale
(VAS), incorporating 3 descriptors, each with speciﬁc
Table 1. Descriptors, Levels, and Deﬁnitions Used as Anchor Points for Evaluating UC
Descriptor
(score most severe lesions) Likert scale anchor points Deﬁnition
Vascular pattern Normal (0) Normal vascular pattern with arborization of capillaries clearly
deﬁned or with blurring or patchy loss of capillary margins
Patchy obliteration (1) Patchy obliteration of vascular pattern
Obliterated (2) Complete obliteration of vascular pattern
Bleeding None (0) No visible blood
Mucosal (1) Some spots or streaks of coagulated blood on the surface of the mucosa
ahead of the scope that can be washed away
Luminal mild (2) Some free liquid blood in the lumen
Luminal moderate or severe (3) Frank blood in the lumen ahead of the endoscope or visible oozing from the mucosa
after washing intraluminal blood, or visible oozing from a hemorrhagic mucosa
Erosions and ulcers None (0) Normal mucosa, no visible erosions or ulcers
Erosions (1) Tiny (5 mm) defects in the mucosa of a white or yellow color with a ﬂat edge
Superﬁcial ulcer (2) Larger (>5 mm) defects in the mucosa, which are discrete ﬁbrin-covered ulcers
when compared with erosions but remain superﬁcial
Deep ulcer (3) Deeper excavated defects in the mucosa with a slightly raised edge
NOTE. The worst affected area of the colon visible at sigmoidoscopy was scored. Although the original version of the UCEIS6 gave a score of 1 to the
normal appearance of a descriptor, a collective decision was made to change the numbering of the levels with normality awarded a score of 0, so that
the simple sum of the UCEIS ranges from 0 to 8.
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and erosions and ulcers (4 levels) (Table 1). The worst disease
area was scored, and the ﬁnal score represented the sum of
the components, with the UCEIS ranging from 3 (normal)
to 11 (most severe). The ﬁrst 2 phases showed very wide
variation in endoscopic interpretation of UC disease severity
between specialists but that 3 descriptors with 11 separate
levels explained 90% of the variance between observers. After
the ﬁrst 2 phases it was concluded that the UCEIS accurately
predicted overall assessment of endoscopic severity of UC,
but that it should be assessed for reliability and validated
before it could be used as an outcome measure in clinical
trials or in routine clinical practice.6
In the present study, we performed an independent
reliability assessment of the UCEIS with a separate cohort
of videos and investigators. The primary objective of the
present study was to assess the reliability of UCEIS scoring
and perform an initial validation in an independent
cohort of videos and investigators after appropriate
training. Secondary objectives included an assessment of
the impact of endoscopists’ knowledge of clinical details
on the evaluation of endoscopic disease severity.Materials and Methods
Terminology
For consistency in the text, the word “index” refers to an
instrument for assessing activity, “descriptor” refers to an item
within that index with severity allocated on a Likert scale, and
“level” refers to the severity graded for an item. “Score” is the
overall measure provided by an index.Development of the UCEIS
Initial development of the UCEIS has been reported.6 In
brief, a library of 670 video sigmoidoscopies from patients with
Mayo Clinic scores of 0 to 11, supplemented by 10 videos from
5 people without UC and 5 hospitalized patients with acute,
severe UC, was used. Phase 1 mapped inconsistency in overall
endoscopic assessment of 16 of 24 video sigmoidoscopies byspecialists (the clinical authors) and deﬁned word for word by
common agreement 10 endoscopic descriptors that evaluated
components of the visual image. Phase 2 was conducted in a
separate cohort of 30 investigators from 13 countries. The in-
vestigators rated descriptors in 25 of 60 randomly assigned
videos and assessed overall endoscopic severity on a VAS from
0 to 100. An index (the UCEIS) consisting of the sum of 3 de-
scriptors, each with 3 or 4 levels of severity, was then constructed
that could be tested for reliability and validation (Table 1).
Interobserver and intraobserver variations in these descriptors
were also quantiﬁed. Phase 3 of the study is reported here.Assessment of the Reliability of the UCEIS
Investigators. Investigators were recruited to reﬂect a
range of geographic and institutional characteristics (see
Acknowledgments) from gastroenterologists known to have
endoscopic training in trials of inﬂammatory bowel disease or
known to the authors to have an interest in endoscopy and in-
ﬂammatory bowel disease. Each investigator was then further
trained to ensure consistency in understanding and use of the
descriptors for assessing endoscopic severity. Training involved
assessing video clips of each descriptor at each level, each with an
agreed deﬁnition of severity. During training, investigators
scored 4 standardized videos from phase 2 that included char-
acteristics of the 3 descriptors. To qualify, investigators had to
identify correctly the level of the descriptor “erosions and ulcers”
on each video and the descriptors “vascular pattern” and
“bleeding” within one level of the correct response on each video.
Investigators failing to qualify at ﬁrst assessment were permitted
one retest that consisted of correctly scoring 2 of 3 different
examples (from different videos) of the descriptor(s) that they
had previously incorrectly scored.
Video selection. Videos performed according to a
standard procedure7,8 were selected (by P.K. and B.R.Y.) from a
resource of videos from clinical trials of patients with active UC.8
Subjects had consented to the anonymized presentation of these
procedures (EUDRACT 2006-001310-32). Each video comprised
a full-length sigmoidoscopy, edited to remove contact friability
test images where present, because this technical test had
confused earlier assessment. Also included were recordings from
subjects (Oxford LREC 536407Q1605/58ORH) without UC
Table 2. Distribution and Allocation of Videos to Investigators in Phase 3
Normal
Mayo Clinic stratum
Most severe Total videos0 1–2 3–5 6–7 8–9 10–11
New videos 4 4 8 8 7 8 7 4 50
Videos used in phase 2 1 0 1 1 1 1 1 1 7
Total no. of videos for evaluation 5 4 9 9 8 9 8 5 57
New videos assigned to each investigator 2 3 3 3 3 3 3 2 22
Duplicates of new videos assigned to investigators Each investigator was assigned 2 videos that
duplicated 2 new videos from among these strata
2a
Videos used in phase 2 assigned to investigators 1 1 1 1 1 1 1 1 2
Duplicates for determining impact of symptom knowledge — — 1 — 1 — 1 — 2
NOTE. “New” refers to videos not previously used in phases 1 and 2.
aEach investigator performed 28 evaluations of 22 new videos, 8 of which were 4 videos scored twice. Two evaluations (of a total of 22 videos and 25
investigators ¼ 550) were missing.
November 2013 PROPERTIES OF THE UCEIS 989
C
LI
N
IC
A
L
A
Tduring colorectal cancer screening (“normal”) and from patients
with the most severe UC who had been hospitalized, some before
emergency colectomy. All videos were anonymized throughout
the study. A library of 57 videos was created and stratiﬁed by
clinical disease activity using the Mayo Clinic score. Fifty of the
videos were new (ie, not previously assessed in phases 1 or 2).
Another 7 were repeated as benchmarks, comprising one each
from extreme strata (ie, normal or most severe) and 5 with Mayo
Clinic scores between 1 and 11.
Video allocation. Each investigator was randomly
assigned 28 of 57 videos in randomized order using a set of Latin
squares (Table 2). Twenty-six of the 28 videos did not include
clinical details. Each investigator was asked to evaluate the
most severely affected area. Two duplicates of new videos (Mayo
Clinic strata 1–2, 6–7, or 10–11) were provided to evaluate
intrainvestigator agreement. Another 2 videos were repeated and
supplemented with clinical details (number of stools/day,
severity of rectal bleeding, pretreatment or posttreatment status,
and physician’s global assessment) to evaluate prior knowledge
of such clinical details on endoscopic evaluation. Videos were
supplied in 3 batches over a 6-week period both to avoid reader
fatigue and to optimize memory extinction for duplicated videos.
Duplicates were arranged so that the ﬁrst of any pair was in the
ﬁrst batch and the second was in the third batch.
Video evaluation. Investigators were asked to evaluate
the 3 descriptors comprising the UCEIS (Table 1) in the area
worst affected at video sigmoidoscopy. In contrast to phase 2,6
still photographs from the training were provided for reference
during evaluation to facilitate reference to the rating standards.
A VAS (0–100) rating overall severity was similar to that used for
phase 2. The VAS was used as a reference in the absence of a gold
standard endoscopic assessment for reasons previously
explained.6 To enable consistent and convenient data entry, in-
vestigators were provided with a data capture program designed
by one of the authors (P.S.) that could be run simultaneously
with video viewing and save responses after each video was
scored. Data ﬁles were e-mailed to the sponsor after qualiﬁcation
assessments and for each cohort.Statistical Analysis
Primary objective. The UCEIS was calculated as the
simple sum of vascular pattern (scored 0–2), bleeding (scored 0 to
3), and erosions and ulcers (scored 0–3). Thus, the range of
possible UCEIS scores was from 0 to 8. (The original version of
the UCEIS6 gave a score of 1 to the normal appearance of a
descriptor, which meant that the total score ranged from 3 to 11.
A collective decision was made to change the numbering of the
levels, such that normality is awarded a score of 0.)The association between the UCEIS (including the descriptors
and the 2 alternative scoring methods) and the evaluation of
overall endoscopic severity by the VAS was quantiﬁed using
Pearson correlation coefﬁcients. Speciﬁcally, each investigator’s
responses for their set of videos were correlated with the mean
overall severity (VAS) for those videos, where video means were
computed using the responses of all other investigators. These
correlations were summarized by median, minimum, and
maximum across investigators. Statistical signiﬁcance was
assumed at a level of 0.05 without adjusting for multiple com-
parisons. Cronbach’s coefﬁcient a, using partial correlation co-
efﬁcients, was calculated for the overall UCEIS score and for the
score with one-at-a-time descriptor deletion to evaluate internal
consistency in the UCEIS.9
Intrainvestigator and interinvestigator agreements for de-
scriptors and the overall UCEIS score were characterized by
k statistics, qualitatively interpreted by Landis and Koch.10 The
standard k summarizing the exact level of agreement was used
for the descriptors. Because the overall UCEIS score represents a
9-level ordinal scale, a weighted k was used, taking into account
close agreement by assigning a weight of 1 for exact agreement,
0.5 for scores that differed by 1 level, and 0 otherwise. Interob-
server k values were calculated by stratifying by investigator pairs
and using the common videos they scored but excluding the
second scoring of duplicate videos. An average of investigator-
pair k values (“overall k”) was calculated, where the weighting
was the inverse of their variance. Intraobserver and interobserver
agreement between the overall evaluation of endoscopic severity
on the VAS and the UCEIS was assessed by reliability ratios (also
known as intraclass correlation coefﬁcients), estimated using
mixed-effect linear models. The reliability ratios for inter-
investigator agreement were estimated using a model with terms
for “investigator,” “video,” and “error”; additional terms for
“investigator-by-video effects” were used to evaluate intra-
investigator agreement.9 Correlation between the UCEIS and
overall severity on the VAS, and all interobserver analyses avoided
data from the second read of duplicate videos between in-
vestigators, and all those where clinical details were provided.
Intraobserver analyses, including those for clinical detail/no
clinical detail pairs, only used data from duplicate videos.
Secondary objectives. The impact of knowledge of
clinical detailswas evaluatedby comparingUCEIS scores andoverall
severity scores on the VAS within the 50 clinical details/no clinical
details pairs. Simple and absolute differences were computedwithin
each pair. t tests were used to test for nonzeromean differences. For
comparison purposes, these analyses were repeated for the duplicate
pairs in which neither video was presented with clinical details.
Analysis of variance with terms for investigator and pair type were
Figure 1. Distribution of overall
endoscopic severity assessed
by a VAS ranging from
0 to 100.
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UCEIS and overall severity, and intraobserver agreement at the
descriptor level, were calculated as described previously. Bowker’s
test for symmetry11 tested for presentation order effects (ie, impact
of viewing videos with clinical details before or after the blinded
version) on responses to descriptors.
Alternative methods for calculation of the
UCEIS. Two additional methods for calculating the UCEIS were
examined:
1. A normalized sum was used, in which descriptors were com-
bined so as to contribute equally, as one-half “vascular
pattern” plus one-third “bleeding” and one-third “erosions
and ulcers”; the range of normalized UCEIS scores was then
0 to 3, with 17 possible scores.
2. An alternative version of UCEIS scoring was used to explore
an expanded scale should the simple UCEIS prove insensitive
to change in the future. Multiple linear regression, with
overall severity as the dependent variable, was used to jointly
estimate weights for the individual descriptors. Modeling was
conducted with investigators treated as ﬁxed effects and de-
scriptors treated as categorical, and as continuous, measures.
Power of differentiation. The design of this study did
not permit a direct evaluation of the UCEIS in terms of sensitivity
to change between videos at the individual patient level. Never-
theless, the data can be analyzed to assess the power of differen-
tiation across patients (videos). All possible pairings of the 57
videoswere formed, for a total of 1596 distinct pairings. Each video
was evaluated by between 6 and 15 investigators in the main
analysis set. For each pair, mean differences in the UCEIS and
overall endoscopic severity on the VAS, and 2-sample t tests for
differences between videos for evaluation of overall severity on the
VAS and the UCEIS were calculated. Proportions of signiﬁcantly
different scores (conﬁrmed by t tests) were studied globally and
as a function of the difference in endoscopic severity on the VAS.Comparison with established clinical measures. To
compare the UCEIS with established clinical measures for UC,
Spearman rank correlation tests were performed between the
UCEIS and full Mayo score, partial Mayo score (excluding endo-
scopic evaluation),12 stool frequency/rectal bleeding, and patient
functional assessment.
Statistical analyses were performed using Statistical Analysis
System (SAS, Cary, NC) software version 9.2.Results
Investigator Qualiﬁcation
Twenty-nine investigators from 14 countries were
screened for participation in the study. Eleven of the 29 suc-
ceeded on ﬁrst qualiﬁcation and 14 on their second attempt.
One investigator failed both times, and 3 were withdrawn due
to noncompliance with procedures, resulting in a total of 25
investigators (11 fromNorth America, 9 fromCentral Europe,
and 5 fromWestern Europe; see Acknowledgments).Video Evaluation
In total, 698 of the planned 700 evaluations were
performed. Each video was assessed by 6 to 15 investigators.
The response rate was 100% for assessment of overall
severity on the VAS and for all descriptors of these 698
evaluations. The analyses that follow exclude 50 videos from
the second evaluation of repeat pairs and the 100 evalua-
tions used for clinical details/no clinical details evaluation,
unless stated otherwise.Range of Disease Severity
Mean overall assessments of endoscopic severity on
the VAS ranged from a score of 0.4 for one video in the
Table 3. Description of Evaluations
Vascular pattern score
Bleeding
score Erosions and ulcers score UCEIS scorea Normalized UCEIS scoreb VAS score (0–100)
Score
0 77 (12.9%) 201 (33.6%) 200 (33.4%) — — —
1 183 (30.6%) 211 (35.3%) 139 (23.2%) — — —
2 338 (56.5%) 126 (21.1%) 175 (29.3%) — — —
3 — 60 (10.0%) 84 (14.0%) — — —
Mean (SD) 2.44 (0.71) 2.08 (0.97) 2.24 (1.06) 6.75 (2.45) 1.89 (0.66) 41.26 (30.41)
Median 3.0 2.0 2.0 7.0 2.0 46.0
Minimum, maximum 1.0, 3.0 1.0, 4.0 1.0, 4.0 3.0, 11.0 0.0, 3.0 0, 100
NOTE. n ¼ 598, excluding duplicate videos.
aThe UCEIS was calculated as a simple sum of the 3 original items: Overall Score¼ (Vascular Pattern Score)þ (Bleeding Score) þ (Erosions and Ulcers
Score).
bThe normalized UCEIS score was calculated as a weighted sum of the 3 original items: Normalized UCEIS Score ¼ (Vascular Pattern Score/2) þ
(Bleeding Score/3) þ (Erosions and Ulcers Score/3).
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videos in the normal stratum, to 93.4 for a video of the
most severe stratum of UC, indicating that the 57 videos
embraced the full range of endoscopic UC severity seen in
clinical trials and practice (Figure 1). Responses also
indicate that the full range of severity was assessed for
each descriptor and on the VAS (Table 3).Table 4
Va
Vascular
Bleeding
Erosions
UCEISb
NOTE. Al
aClinical
assessm
agreeme
bWeighteInitial Validation of the UCEIS
The correlation of the simple sum version of the
UCEIS with evaluation of overall severity on the VAS had a
median of 0.93 across investigators (minimum, 0.78;
maximum, 0.99), indicating that on average the UCEIS
captured 86% (derived from 0.932) of the variance in in-
vestigators’ assessments of overall severity. There was also
a high level of correlation between the 3 individual de-
scriptors and assessment of overall severity on the VAS:
with a median of 0.82 (minimum, 0.55; maximum, 0.90)
for vascular pattern, 0.80 (minimum, 0.45; maximum,
0.97) for bleeding, and 0.89 (minimum, 0.78; maximum,
0.96) for erosions and ulcers.Internal Consistency of the UCEIS
The Cronbach coefﬁcient a was 0.863 for the UCEIS
overall (vascular pattern, 0.83; bleeding, 0.80; erosions and
ulcers: 0.79). One-at-a-time deletion of descriptors resulted
in slightly lower a coefﬁcients (0.79–0.83), indicating that
each descriptor contributed positively to the overall UCEIS.. Intrainvestigator and Interinvestigator Agreement and Effect of Kno
riable
Intrainvestigator agreement
(n ¼ 50 pairs of repeat evaluations)
Interinvestig
(n ¼ 548
pattern 0.87 (0.74–1.00) 0.54 (0
0.47 (0.27–0.67) 0.48 (0
and ulcers 0.81 (0.67–0.94) 0.53 (0
0.72 (0.61–0.82) 0.50 (0
l values are expressed as k value (95% CI).
details included age, sex, number of stools/day, severity of rectal bleeding
ent. Interpretation of standard k: <0.20, poor agreement; 0.21–0.40, fair
nt; 0.81–1.00, very good agreement.10
d k for full 0–8 UCEIS scale; weight ¼ 1.0 for exact agreement, 0.5 for difIntrainvestigator and Interinvestigator
Agreement for the UCEIS
A total of 50 repeat-pair assessments assessed
intraobserver variability. The intrainvestigator reliability
ratio for evaluation of overall severity was 0.87 on the VAS
and 0.96 for the UCEIS. Intrainvestigator agreement for
descriptors ranged from a k of 0.47 (95% conﬁdence in-
terval [CI], 0.27–0.67) for bleeding to 0.87 (95% CI,
0.74–1.00) for vascular pattern (Table 4), indicating
moderate to very good agreement for individual de-
scriptors. The weighted intraobserver k for the overall
UCEIS score was 0.72 (95% CI, 0.61–0.82). A total of
548 video evaluations of 57 videos (22 per investigator,
2 missing; Table 2) assessed interobserver variability. The
interinvestigator reliability ratio for overall assessment
of severity was 0.78 on the VAS and 0.88 for the UCEIS.
Interinvestigator agreement for descriptors ranged from a
k of 0.48 (95% CI, 0.46–0.50) for bleeding to 0.54 (95% CI,
0.50–0.57) for vascular pattern, indicating moderate
agreement for individual descriptors between investigators
(Table 4). The weighted interobserver k for the overall
UCEIS score was 0.50 (95% CI, 0.49–0.52). In summary,
only 4% of the variation in UCEIS scoring in the repeat
evaluation data set was attributable to within-investigator
variation when scoring the same video twice. Similarly,
only 12% of the variation in UCEIS scoring in the main
analysis data set was attributable to investigator-to-
investigator differences when scoring a common video.wledge of Clinical Details on Intrainvestigator Agreement
ator agreement
evaluations)
Clinical detailsa/no clinical details pairs
(n ¼ 50 pairs of evaluations)
.50–0.57) 0.79 (0.63–0.94)
.46–0.50) 0.64 (0.47–0.80)
.51–0.57) 0.72 (0.56–0.88)
.49–0.52) 0.68 (0.56–0.80)
, pretreatment or posttreatment status, and physician’s global
agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good
ference of 1 level, and 0 otherwise.
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Across investigators, the correlation between the
normalized version of the UCEIS and overall severity
(VAS) had a median value of 0.94 (minimum, 0.78;
maximum, 0.98), very similar to that for the standard
UCEIS scoring. The intrainvestigator and interinvestigator
reliability ratios were 0.96 and 0.88, respectively, the same
as for the 9-level standard UCEIS scoring.
Regression modeling identiﬁed an alternative scoring
method with unequal descriptor weightings for the UCEIS
that also has a high correlation with the overall evaluation
of endoscopic severity. Speciﬁcally, a weight of 15 applied
to the erosions descriptor and 10 to each of the bleeding
and vascular pattern descriptors resulted in a UCEIS scale
with 18 possible levels and a median (minimum,
maximum) correlation across investigators of 0.93 (0.81,
0.99) with overall severity. The intrainvestigator and
interinvestigator reliability ratios were 0.96 and 0.88,
respectively, the same as for the 9-level standard UCEIS
scoring. The Cronbach a for internal consistency
decreased from 0.86 to 0.81.Effect of Clinical Knowledge
The mean difference of UCEIS scores within the
50 clinical details/no clinical details pairs was 0.20
(SD, 0.95; P ¼ .14); for overall score (VAS), the mean
difference was 1.82 (SD, 15.23; P ¼ .40). The absolute
differences in UCEIS were 0 or 1 in 45 of the 50 pairs
(90%), with a maximum of 4. The mean absolute differ-
ence in overall severity was 10.4 (SD, 11.2). The corre-
sponding statistics for the repeat pairs in which neithervideo had accompanying clinical detail information pro-
vided were as follows: mean UCEIS difference of 0.06 (SD,
0.68; P ¼ .54), mean overall severity difference of 3.18 (SD,
14.6; P ¼ .13), absolute difference in UCEIS of 0 (n ¼ 49;
98%) or 1 (n ¼ 1; 2%), and the absolute difference in mean
overall severity of 11.3 (SD, 9.7).
The absolute UCEIS differences within the clinical de-
tails/no clinical details pairs did not differ signiﬁcantly
from those within the regular repeated pairs (analysis of
variance, P ¼ .45) or for overall severity on the VAS
(ANOVA, P ¼ .68). For the clinical details/no clinical
details pairs, the intrainvestigator reliability ratio for
evaluation of overall severity was 0.87 on the VAS and 0.93
for the UCEIS. Intrainvestigator agreement with the clin-
ical details/no clinical details pairs was a k of 0.64 (95% CI,
0.47–0.80) for bleeding, 0.79 (95% CI, 0.63–0.94) for
vascular pattern, and 0.72 (95% CI, 0.56–0.88) for erosions
and ulcers (Table 4). The weighted k for the overall UCEIS
score within the clinical details/no details pairs was 0.68
(95% CI, 0.56–0.80), very similar to the value of k ¼ 0.72
within repeat pairs in which neither video had accompa-
nying clinical details. Viewing the video with clinical de-
tails before or after the same video without such did not
affect the results (P > .30 for all descriptors).Power of Differentiation
There was a statistically signiﬁcant difference in
mean UCEIS score between videos in 77.3% of the pair-
ings, compared with 71.6% for evaluation of overall
severity on the VAS. Figure 2 relates the difference in
evaluation of overall severity on VAS between video pairsFigure 2. Power of differentia-
tion. The ﬁgure relates the mean
difference in overall severity
between videos measured on
the VAS (x-axis) to statistical
signiﬁcance (P  .05) of the
mean difference of UCEIS be-
tween videos (y-axis). When the
mean difference in overall
severity between 2 videos
reached 20 units on the VAS,
the mean difference in UCEIS
between those 2 videos was
statistically signiﬁcant approxi-
mately 80% of the time and
reached 90% when the mean
difference was 25 units on the
VAS.
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difference of the UCEIS between video pairs (y-axis). When
the mean difference in overall severity between 2 videos
reached 20 units on the VAS, the mean difference in the
UCEIS between those 2 videos was statistically signiﬁcant
approximately 80% of the time and reached 90% when the
overall difference in severity was 25 units.Table 5
Full May
Partial M
Stool fre
Patient f
NOTE. Th
for whic
available
A
TFinal Version of the UCEISC
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LThe simple sum of different levels of severity was
performed as well as a normalized version of calculating
the UCEIS, maintaining it as the favored version, with a
total score ranging from 0 to 8 (Table 1).Comparison with Established Clinical
Measures
Correlations of the ﬁnal version of the UCEIS were
performed against the full Mayo score, partial Mayo score
(excluding endoscopic evaluation), stool frequency/rectal
bleeding, and patient functional assessment. Spearman
rank correlations ranged from 0.57 (95% CI, 0.51–0.63) for
patient functional assessment to 0.73 (95% CI, 0.68–0.77)
for the full Mayo score (Table 5).Discussion
The UCEIS is a reliable instrument for measuring
the endoscopic disease activity of UC. After initial assess-
ment for validity, it also appears to be valid, but additional
validity testing is needed. Just 3 descriptors (each with 3 or
4 levels of severity) accounted for 86% of the variance in
the overall assessment of endoscopic severity. Given the
enormous variance in assessment between specialists in
the initial evaluation,6 this represents substantial progress.
Correlation of the UCEIS with established UC activity
scores was shown to be moderate (stool frequency/rectal
bleeding: 0.67 [95% CI, 0.61–0.72]; patient functional
assessment, 0.57 [95% CI, 0.51–0.63]) or strong (Mayo
score, 0.73 [95% CI, 0.68–0.77]; partial Mayo score, 0.70
[95% CI, 0.64–0.74]). This provides additional support for
the performance of the UCEIS using just 3 descriptors
(Table 5).
Mean overall assessments of endoscopic severity indi-
cated that the 57 videos, evaluated by an independent
cohort of 25 investigators from 14 countries (more than
half of whom came from North America or Western
Europe), were representative of the full range of endoscopic. Spearman Rank Correlations With the Final Version of
the UCEIS
Comparator Correlation 95% CI
o score 0.73 (0.68–0.77)
ayo score 0.70 (0.64–0.74)
quency and rectal blood 0.67 (0.61–0.72)
unctional assessment 0.57 (0.51–0.63)
ese analyses exclude the “normal” and “most severe” subjects
h the Mayo and patient functional assessment data were not
.UC severity seen in clinical practice. Internal consistency
(Cronbach coefﬁcient a of 0.86) was good-excellent (ie,
>0.70) for the descriptors in the index.11 Across in-
vestigators, correlation between the overall evaluation of
endoscopic severity on the VAS and the UCEIS was excep-
tionally high (median Pearson correlation coefﬁcient of
0.93). The lack of a true gold standard for assessing
endoscopic severity of UC was an inevitable shortcoming of
the study, so the overall severity assessed on the VAS was
used as a reference. It is conceivable that correlation was
enhanced by contemporary scoring of both descriptors and
the VAS, but the lack of a training calibration for scoring
the VAS would have detracted from the correlation.
Nevertheless, potential bias was examined by correlating
each investigator’s responses for their set of videos with the
mean VAS for those videos, computed from the responses
of all other investigators. Median correlations ranged from
0.80 to 0.93, which suggests that the UCEIS is likely to be a
valid assessment of endoscopic severity.
Intrainvestigator and interinvestigator reliability ratios
for the UCEIS were 0.96 and 0.88, respectively, each better
than overall severity as measured by the VAS. Intra-
observer agreement for each descriptor was moderate to
very good (k of 0.47 [95% CI, 0.27–0.67] for bleeding to
0.87 [95% CI, 0.74–1.00] for vascular pattern) and good for
the overall UCEIS score (weighted k of 0.72 [95% CI,
0.61–0.82]). Interinvestigator agreement was rated as
moderate for all descriptors and moderate for the 9-level
UCEIS as a whole (weighted k of 0.50 [95% CI,
0.49–0.52]). It may seem surprising that scoring of
bleeding was most subject to variation by the same
observer. This may have been the result of investigators’
misinterpretation of the descriptions used to deﬁne the
level of bleeding. Alternatively, this variation may be
because investigators did not appreciate the importance of
scoring bleeding during insertion of the ﬂexible sigmoid-
oscope, despite being directed to do so to avoid confusion
with contact bleeding. Importantly, however, there was no
signiﬁcant difference in k statistics between descriptors.
Indeed, it is remarkable that this was the only unexpected
result in a study notable for a good level of consistency.
Our data suggest that the key to consistent evaluation
of endoscopic severity between observers is a standardized
system of description. Training is another component.
Other work has reported that scores for interobserver and
intraobserver weighted k statistics using established
indices are all lower for trainee endoscopists than for
specialists, indicating that assessment of disease activity
beneﬁts from experience.13 Assessment of a total of 28
videos could therefore be subject to a training effect,
which might bias ﬁndings in later assessments. To limit
such bias, all investigators underwent initial training and
qualiﬁcation, the order of all videos (including duplicates)
was randomized, and the videos were provided in 3 sepa-
rate batches separated by time to optimize memory
extinction between video reading sessions.
Nevertheless, there were anomalies. Normal videos
received a higher mean VAS score than those from some
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Tpatients (Figure 1), although a normal endoscopy is
entirely consistent with UC in remission and this must
reﬂect variation around normality. The more important
point is that 25 independent investigators evaluated 57
endoscopies and that the range of overall severity on a
scale from 0 to 100 was 0.4 to 93.4, indicating that the
selected endoscopies gave as wide a range of severity for
assessment as reasonably possible. It is conceivable that
physician knowledge of clinical information might inﬂu-
ence endoscopic assessment.14 For the UCEIS, knowledge
of symptoms had a modest effect overall, although, as
might be expected, this had the greater effect on the
bleeding descriptor. In the 50 repeat pairs of videos,
agreement in the rectal bleeding score between the 2
readings improved from a k of 0.47 (95% CI, 0.27–0.67) to
0.64 (95% CI, 0.47–0.80) (Table 4) when symptoms were
known, but the numbers are small. It is understandable
that if symptoms of rectal bleeding are present, then the
threshold for describing bleeding at endoscopy (and
therefore variability in that description) is reduced.
Further evaluation of the impact of clinical details on
endoscopists’ assessment in UC is warranted.
Sensitivity to change is a valuable property of an index and
is best achieved by comparing the delta change to the
assessment of variance in patients unchanged after treat-
ment of known efﬁcacy. This needs to be assessed in a pro-
spective clinical trial, although statistical analysis in the
current cohort showed that the UCEIS was signiﬁcantly
different 90% of the time when the overall severity on the
VAS differed by 25 points. The clinical relevance of this
modeling must be regarded as uncertain. In a further step
toward its place in research, training, and clinical practice,
the UCEIS is currently undergoing development by the Eu-
ropean Crohn’s and Colitis Organisation as a training tool.
This study is a ﬁrst step in the validation of the UCEIS. It
has conﬁrmed the reliability of the UCEIS, even if further
validation is needed to establish thresholds for remission,
the clinical relevance of different UCEIS scores, and
responsiveness of the UCEIS to change in disease status.
The UCEIS is based on evaluation of the most severely
affected area at ﬂexible sigmoidoscopy. It is as yet unclear
how an overall score might be affected by full colonoscopy
or whether it might be applied in colonic segments.15,16
Colonoscopy could result in a higher UCEIS than
sigmoidoscopy simply because a larger area is examined;
because scoring is applied to the area of maximum severity,
if that area lies proximal to the rectosigmoid colon, the
score would increase de facto. This might, in turn, alter the
overall evaluation of endoscopic severity. The UCEIS
showed consistency in endoscopic evaluation and, if it can
be shown to correspond with histological disease activity or
validated biomarkers, may facilitate the use of smaller
sample sizes in clinical trials due to increased statistical
power derived from this consistency. If the UCEIS can
demonstrably affect decision making or predict clinical
outcome, then this will amplify its role in clinical practice.
The UCEIS reliably evaluates the overall endoscopic
severity of UC and accounts for 88% of the variancebetween endoscopists. It is simple to use, based on the
sum of 3 descriptors with a score ranging from 0 to 8. The
thresholds for severity and remission remain to be deﬁned,
as does the responsiveness to change. In conjunction with
a training package to protect the reliability of scoring, it is
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